0N6A Stock Chart & Stats
€0.06
<€0.01(3.51%)
At close: 4:00 PM EDT
€0.06
<€0.01(3.51%)
Day’s Range― - ―
52-Week Range€0.03 - €0.18
Previous CloseN/A
Volume0.00
Average Volume (3M)2.17K
Market Cap
€12.23M
Enterprise Value€7.83M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.39M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,188,980
10 Day Avg. Volume6,486
30 Day Avg. Volume2,172
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused CNS Oncology StrategyA concentrated focus on CNS cancers can help align research, translational work and clinical development around a defined unmet need, supporting more coherent use of limited resources over the medium term.
Historical Loss And Burn ImprovementAlthough the company remains loss-making and burn worsened in 2025, prior improvement indicates some capacity to reduce spending intensity, which could extend operational runway if sustained.
Clinical Pipeline And Partnering PotentialAdvancing candidates through development creates potential value from clinical milestones, future licensing or partnerships, and eventual commercialization, although the pack provides no evidence of successful validation yet.
Bears Say
Pre-commercial Revenue WeaknessThe absence of recurring commercial revenue leaves the business dependent on pipeline progress and external capital, limiting financial resilience and making near-term operating performance structurally difficult to sustain.
Negative Equity And Rising DebtNegative equity and higher debt weaken solvency and financing flexibility, increasing dependence on new funding and raising the risk that future capital needs could materially dilute existing shareholders.
Persistent Cash BurnContinuous operating and free-cash-flow deficits show that internal cash generation does not currently support development, leaving the company reliant on external funding to maintain its research pipeline.
TME Pharma N.V. News
0N6A FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.03 and its highest was €0.18 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €12.23M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were TME Pharma N.V.’s earnings last quarter?
Currently, no data Available
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,188,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in DE:0N6A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―